Published in Proc Natl Acad Sci U S A on May 01, 1979
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev (1995) 1.90
Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis (1985) 1.88
Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev (1988) 1.78
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Microbiota, disease, and back to health: a metastable journey. Sci Transl Med (2012) 1.70
Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV). Am J Pathol (1982) 1.66
Amplification and novel locations of endogenous mouse mammary tumor virus genomes in mouse T-cell lymphomas. J Virol (1984) 1.63
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. Am J Pathol (1983) 1.51
Inverted repeat nucleotide sequences in the genomes of Marek disease virus and the herpesvirus of the turkey. Proc Natl Acad Sci U S A (1982) 1.39
Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia: a model for the origin and progression of malignancy. Proc Natl Acad Sci U S A (1980) 1.35
Epstein-Barr virus infection and human malignancies. Int J Exp Pathol (2001) 1.24
Murine Ly-6 multigene family is located on chromosome 15. Proc Natl Acad Sci U S A (1987) 1.20
Cell-surface-antigen mutants of haematopoietic cells. Tools to study differentiation, biosynthesis and function. Biochem J (1985) 1.05
Clonal analysis of the late stages of erythroleukemia induced by two distinct strains of Friend leukemia virus. Mol Cell Biol (1981) 1.00
Increased responses to lymphokines are correlated with preleukemia in mice inoculated with Moloney leukemia virus. Proc Natl Acad Sci U S A (1981) 1.00
Epstein-Barr-virus-carrying lymphoma in a patient with ataxia-telangiectasia. Br Med J (Clin Res Ed) (1981) 0.98
Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. J Clin Invest (1987) 0.97
Sensitive radioimmune assay for measuring Aleutian disease virus antigen and antibody. J Clin Microbiol (1983) 0.97
Immunopathology of natural and experimental lymphomas induced by wild mouse leukemia virus. Am J Pathol (1981) 0.95
Herpesvirus ateles and herpesvirus saimiri transform marmoset T cells into continuously proliferating cell lines that can mediate natural killer cell-like cytotoxicity. Proc Natl Acad Sci U S A (1981) 0.88
Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine. Clin Exp Immunol (1983) 0.88
Malignant transformation of Bloom syndrome B-lymphoblastoid cell lines by carcinogens. Proc Natl Acad Sci U S A (1985) 0.84
Epstein-Barr virus in a CD8-positive T-cell lymphoma. Am J Pathol (1990) 0.84
The cellular ecology of progressive neoplastic transformation: a clonal analysis. Proc Natl Acad Sci U S A (1999) 0.83
Immune deficiency as a risk factor in Epstein-Barr virus-induced malignant diseases. Environ Health Perspect (1990) 0.83
Bloom syndrome B-lymphoblastoid cells are hypersensitive towards carcinogen and tumor promoter-induced chromosomal alterations and growth in agar. EMBO J (1985) 0.82
Infectious mononucleosis in the nasopharynx with a histological picture of malignant lymphoma. Arch Otorhinolaryngol (1988) 0.81
A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal. Adv Hematol (2011) 0.80
Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. BMC Clin Pathol (2009) 0.80
Suppression of malignancy in human cancer cells: issues and challenges. Proc Natl Acad Sci U S A (1981) 0.78
Familial Burkitt's lymphoma in Papua New Guinea. Br J Cancer (1997) 0.75
Cytoplasmic transfer of DNA containing simian virus 40 sequences into mouse 3T3 cells. Proc Natl Acad Sci U S A (1980) 0.75
Histiocytic Lymphoma in Renal Transplant Patients Receiving Cyclosporine. Transplant Proc (1983) 0.75
Chemical carcinogens: a review of the science and its associated principles. U.S. Interagency Staff Group on Carcinogens. Environ Health Perspect (1986) 0.75
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature (1976) 9.81
Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci U S A (1975) 7.27
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A (1975) 4.21
Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature (1978) 3.73
Transformation and chromosome changes induced by Epstein-Barr virus in normal human leukocyte cultures. Proc Natl Acad Sci U S A (1969) 3.72
Marker band in one chromosome 14 from Burkitt lymphomas. Nature (1972) 3.59
Malignant lymphoma in African children. II. A pathological entity. Cancer (1961) 3.45
Suppression of malignancy by cell fusion. Nature (1969) 3.41
Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol (1968) 3.09
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer (1971) 2.96
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
On the mechanism of polyoma virus-induced synthesis of cellular DNA. Proc Natl Acad Sci U S A (1965) 2.67
Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol (1972) 2.18
Classification and biological nature of established human hematopoietic cell lines. Int J Cancer (1975) 2.16
Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature (1976) 2.10
Oncogenic Herpes viruses. Biochim Biophys Acta (1975) 2.01
Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus. J Natl Cancer Inst (1969) 1.95
Induction of cellular DNA synthesis in human leukocytes by Epstein-Barr virus. Nature (1971) 1.91
Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer (1977) 1.84
Trisomy of chromosome 15 in spontaneous leukemia of AKR mice. Proc Natl Acad Sci U S A (1975) 1.84
EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer (1976) 1.81
Human lymphoblastoid cell lines derived from individuals without lymphoproliferative disease contain the same latent forms of Epstein-Barr virus DNA as those found in tumor cells. Int J Cancer (1977) 1.67
Assay for Epstein-Barr virus based on stimulation of DNA synthesis in mixed leukocytes from human umbilical cord blood. J Virol (1975) 1.66
Purification of the Epstein-Barr virus-determined nuclear antigen from Epstein-Barr virus-transformed human lymphoid cell lines. J Virol (1978) 1.65
Chromosome mapping of the genes that control differentiation and malignancy in myeloid leukemic cells. Proc Natl Acad Sci U S A (1977) 1.64
Somatic rearrangement of chromosome 14 in human lymphocytes. Proc Natl Acad Sci U S A (1975) 1.61
SIGNIFICANCE OF CONTINUED VIRUS PRODUCTION IN TISSUE CULTURES RENDERED NEOPLASTIC BY POLYOMA VIRUS. Proc Natl Acad Sci U S A (1960) 1.61
The natural history of cancer. J Chronic Dis (1958) 1.60
Characteristics of new cell lines derived from Burkitt lymphomas. Cancer (1969) 1.46
The analysis of malignancy by cell fusion. I. Hybrids between tumour cells and L cell derivatives. J Cell Sci (1971) 1.45
Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med (1973) 1.42
Human lymphoblastoid cell lines and Epstein-Barr virus: a review of their interrelationships and their relevance to the etiology of leukoproliferative states in man. Yale J Biol Med (1971) 1.38
Epstein-Barr virus and nonhuman primates: natural and experimental infection. Adv Cancer Res (1976) 1.37
Antigens and DNA of a chimpanzee agent related to Epstein-Barr virus. J Virol (1976) 1.37
Temperature-sensitive mutations in animal cells. Adv Cancer Res (1977) 1.36
The analysis of malignancy by cell fusion. VII. Cytogenetic analysis of hybrids between malignant and diploid cells and of tumours derived from them. J Cell Sci (1977) 1.35
Induction of EBNA precedes the first cellular S-phase after EBV-infection of human lymphocytes. Int J Cancer (1978) 1.35
Chromosome changes (trisomies #15 and 17) associated with tumor progression in leukemias induced by radiation leukemia virus. J Natl Cancer Inst (1978) 1.22
Comparison between growth characteristics of an Epstein--Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro. Proc Natl Acad Sci U S A (1975) 1.18
Failure of human cells transformed by simian virus 40 to form tumors in athymic nude mice. Proc Natl Acad Sci U S A (1975) 1.18
The analysis of malignancy by cell fusion. 3. Hybrids between diploid fibroblasts and other tumour cells. J Cell Sci (1971) 1.17
Foreign-cell contamination in Burkitt tumours. Lancet (1971) 1.16
Cytogenetic mapping of the trisomic segment of chromosome 15 in murine T-cell leukaemia. Nature (1978) 1.14
Detection of a nuclear, EBNA-type antigen in apparently EBNA-negative Herpesvirus papio (HVP)-transformed lymphoid lines by the acid-fixed nuclear binding technique. Int J Cancer (1977) 1.14
Chromosome changes (trisomy 15) in murine T-cell leukemia induced by 1,12-dimethylbenz(a)anthracene (DMBA). Int J Cancer (1978) 1.11
Simian herpesviruses and neoplasia. Adv Cancer Res (1974) 1.08
Association of Epstein-Barr viral genomes with American Burkitt lymphoma. Nature (1976) 1.08
Cell fusion and the analysis of malignancy. Proc R Soc Lond B Biol Sci (1971) 1.06
Correlation between balance of specific chromosomes and expression of malignancy in hamster cells. J Natl Cancer Inst (1975) 1.05
Further characterization of a herpesvirus-positive orang-utan cell line and comparative aspects of in vitro transformation with lymphotropic old world primate herpesviruses. Int J Cancer (1978) 1.05
Killer T cells in a Burkitt's lymphoma biopsy. Nature (1975) 1.04
Further studies on the differences in serum dependence in EBV negative lymphoma lines and their in vitro EBV converted, virus-genome carrying sublines. Eur J Cancer (1977) 1.01
Malignancy and transformation: expression in somatic cell hybrids and variants. Adv Cancer Res (1977) 1.00
Differences in the ConA-induced redistribution and agglutination patterns of EBV genome-free and EBV-carrying human lymphoma lines. Exp Cell Res (1977) 0.99
Studies on the Epstein-Barr Virus genome and the EBV-determined nuclear antigen in human malignant disease. Cold Spring Harb Symp Quant Biol (1975) 0.99
Clustering of aberrations to specific chromosomes in human neoplasms. III. Incidence and geographic distribution of chromosome aberrations in 856 cases. Hereditas (1978) 0.98
Erythrocytic maturation of (Friend) virus-induced leukemic cells in spleen clones. Proc Natl Acad Sci U S A (1967) 0.93
Difference in antibody induced redistribution of membrane IgM in EBV geonome free and EBV positive human lymphoid cells. Exp Cell Res (1976) 0.92
EBV specific killer T cells and serologic responses after onset of infectious mononucleosis. J Clin Lab Immunol (1978) 0.90
Transformation of lymphocytes by Herpesvirus papio. Int J Cancer (1977) 0.90
Chromosome 14 translocations in non-Burkitt lymphomas. Int J Cancer (1978) 0.89
EBV-related cytotoxicity of Fc receptor negative T lymphocytes separated from the blood of infectious mononucleosis patients. Cancer Lett (1978) 0.88
Chromosome 14 translocation in African and North American Burkitt's lymphoma;. Int J Cancer (1977) 0.87
Chromosomal control of malignancy in tumours from cells transformed by polyoma virus. Int J Cancer (1973) 0.84
Epstein-Barr-virus immunity and tissue distribution in a fatal case of infectious mononucleosis. N Engl J Med (1978) 0.83
Origin of the translocated segment of the 14q+ marker in non-Burkitt lymphomas. Hum Genet (1977) 0.81
Karyotype peculiarities of malignant lymphomas. Hum Genet (1977) 0.81
A 14q+ marker and a late replicating chromosome No. 22 in a brain tumor: brief communication. J Natl Cancer Inst (1977) 0.77
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet (2006) 7.88
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
The role of gene dosage and genetic transpositions in carcinogenesis. Nature (1981) 5.58
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A (1974) 5.13
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell (1983) 4.22
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Suppression of malignancy by cell fusion. Nature (1969) 3.41
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med (1968) 3.01
Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer (1971) 3.00
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer (1971) 2.96
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer (1972) 2.80
Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res (1982) 2.68
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (1977) 2.58
Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection. Clin Exp Immunol (1974) 2.57
EB virus-induced B lymphocyte cell lines producing specific antibody. Nature (1977) 2.56
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood (1999) 2.49
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol (1979) 2.31
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
Linear association between cellular DNA and Epstein-Barr virus DNA in a human lymphoblastoid cell line. Proc Natl Acad Sci U S A (1973) 2.27
Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst (1973) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Tumor antigens. Annu Rev Microbiol (1966) 2.19
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines. Int J Cancer (1971) 2.18
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome. Int J Cancer (1973) 2.14
Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A (1988) 2.12
Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int J Cancer (1974) 2.10
Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature (1976) 2.10
Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit. J Virol (1980) 2.07
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1973) 2.02
Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines. Cancer Res (1967) 2.01
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.99
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int J Cancer (1975) 1.95
Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med (1984) 1.94
A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics (1972) 1.93
Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene (1993) 1.91
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
High-level expression of the Epstein-Barr virus EBNA1 protein in CV1 cells and human lymphoid cells using a SV40 late replacement vector. Gene (1986) 1.90
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer (1977) 1.84
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation (2001) 1.83
Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med (1985) 1.83
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer (1976) 1.81
Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice. Int J Cancer (1973) 1.80
Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood (2000) 1.78
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A (1988) 1.76
Immunological factors affecting tumour growth. Br Med J (1970) 1.75
Solubilization of the Epstein-Barr virus-determined nuclear antigen and its characterization as a DNA-binding protein. J Virol (1977) 1.75
Herpesviruses and oncogenesis. Proc Natl Acad Sci U S A (1972) 1.74
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer (1989) 1.74
p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci U S A (1994) 1.74
The Epstein-Barr virus and neoplasia. N Engl J Med (1975) 1.72
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol (1969) 1.68
Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology (1971) 1.68
Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells. J Virol (1985) 1.66
Purification of the Epstein-Barr virus-determined nuclear antigen from Epstein-Barr virus-transformed human lymphoid cell lines. J Virol (1978) 1.65
Sinus node-atrioventricular node isolation: long-term results with the "corridor" operation for atrial fibrillation. J Am Coll Cardiol (1991) 1.65
Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A (1987) 1.63
The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J Virol (1996) 1.61
Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. J Natl Cancer Inst (1966) 1.61
Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture. Cancer Res (1968) 1.61
Two-colour immunofluorescence studies on EBV-determined antigens. Clin Exp Immunol (1971) 1.60
Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer (1977) 1.58
Surface markers on human B and T-lymphocytes. IX. Two-color immunofluorescence studies on the association between ebv receptors and complement receptors on the surface of lymphoid cell lines. Int J Cancer (1976) 1.58
Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int J Cancer (1970) 1.57